Literature DB >> 21449006

Role of COMT, 5-HT(1A) , and SERT genetic polymorphisms on antidepressant response to Transcranial Magnetic Stimulation.

Alessia Malaguti1, David Rossini, Adelio Lucca, Lorenzo Magri, Cristina Lorenzi, Adele Pirovano, Christina Colombo, Enrico Smeraldi, Raffaella Zanardi.   

Abstract

BACKGROUND: Transcranial Magnetic Stimulation (TMS) is an effective technique in the treatment of depression, specifically in drug-resistant patients. However, there is little data available on the influence of genetic variables on TMS response.
METHODS: We analyzed the role of three genetic polymorphisms that affected the antidepressant response: serotonin transporter promoter region (SERTPR) polymorphism, 5-HT(1A) serotonergic receptor promoter region polymorphism (rs6295), and the coding region of COMT gene polymorphism (rs4680). Ninety patients with a major depressive drug-resistant episode due to a Major Depressive Disorder or to a Bipolar Disorder were included in our study. Patients underwent high frequency TMS, focused on the left prefrontal cortex, for 2 weeks. At study completion, the response rate was 45.5%. Effects of gene polymorphisms on clinical improvement were analyzed with an analysis of variance with each gene (SERTPR, 5-HT(1A) , and COMT) as factors and the Hamilton Rating Scale for Depression variation from baseline to the end of the treatment as a dependent variable.
RESULTS: We found a significant model in which three factors were not significant (diagnosis, COMT, and SERTPR), whereas factor 5-HT(1A) showed a significant influence on the outcome, with patients with C/C genotype showing a greater improvement than G/G and C/G and no difference between G/G and C/G.
CONCLUSION: According to our data, 5-HT(1A) polymorphism may play a role in influencing TMS response. The effect of COMT and SERTPR did not reach statistical significance. The analysis of these and other candidate genes in larger samples could help explain genetic influence on TMS response.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21449006     DOI: 10.1002/da.20815

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  15 in total

Review 1.  Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

Authors:  Paul R. Albert; Brice Le François; Faranak Vahid-Ansari
Journal:  J Psychiatry Neurosci       Date:  2019-05-01       Impact factor: 6.186

2.  Identification of Clinical Features and Biomarkers that may inform a Personalized Approach to rTMS for Depression.

Authors:  Sarah L Garnaat; Andrew M Fukuda; Shiwen Yuan; Linda L Carpenter
Journal:  Pers Med Psychiatry       Date:  2019-10-18

3.  Genetic profile for dopamine signaling predicts brain functional reactivity to repetitive transcranial magnetic stimulation.

Authors:  Haejin Hong; Rye Young Kim; Soo Mee Lim; Suji Lee; Yumi Song; Chaewon Suh; Hyangwon Lee; In Kyoon Lyoo; Sujung Yoon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-08-11       Impact factor: 5.760

Review 4.  Personalizing neuromodulation.

Authors:  John D Medaglia; Brian Erickson; Jared Zimmerman; Apoorva Kelkar
Journal:  Int J Psychophysiol       Date:  2019-01-24       Impact factor: 2.997

Review 5.  Biological markers in noninvasive brain stimulation trials in major depressive disorder: a systematic review.

Authors:  Thiago M Fidalgo; J Leon Morales-Quezada; Guilherme S C Muzy; Noelle M Chiavetta; Mariana E Mendonca; Marcus V B Santana; Oscar F Goncalves; Andre R Brunoni; Felipe Fregni
Journal:  J ECT       Date:  2014-03       Impact factor: 3.635

Review 6.  Transcriptional dys-regulation in anxiety and major depression: 5-HT1A gene promoter architecture as a therapeutic opportunity.

Authors:  Paul R Albert; Laura M Fiori
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  Serotonergic gene-to-gene interaction is associated with mood and GABA concentrations but not with pain-related cerebral processing in fibromyalgia subjects and healthy controls.

Authors:  Rouslan Sitnikov; Eva Kosek; Isabel Ellerbrock; Angelica Sandström; Jeanette Tour; Silvia Fanton; Diana Kadetoff; Martin Schalling; Karin B Jensen
Journal:  Mol Brain       Date:  2021-05-12       Impact factor: 4.041

8.  Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model

Authors:  Adam Pettitt
Journal:  eNeuro       Date:  2015-06-05

9.  Serotonin-1A receptor polymorphism (rs6295) associated with thermal pain perception.

Authors:  Fredrik Lindstedt; Bianka Karshikoff; Martin Schalling; Caroline Olgart Höglund; Martin Ingvar; Mats Lekander; Eva Kosek
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

10.  The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder.

Authors:  Andrew F Leuchter; Ian A Cook; Yi Jin; Bill Phillips
Journal:  Front Hum Neurosci       Date:  2013-02-26       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.